World CDx 2026 has ended. This guide stays up as the record of who was there. Next: World CDx 2027, Aug 30 – Sep 2, 2027 in Boston
Liquid biopsy and MRD at World CDx 2026
Oct 5–8, 2026 Boston, MA ~900 attendees Website
24 organizations at World CDx 2026 present work in liquid biopsy & MRD: 15 technology and service providers, 7 drug developers and 2 academic, government and non-profit bodies. Between them they bring 48 presentations to the program. Most represented: Johnson & Johnson Innovative Medicine (7 on the program), EMD Serono (4 on the program), Merck (4 on the program). As of Oct 8, 2026.
Format
Top represented
Showing 1–10 of 24 organizations
| Organization | World CDx 2026 Attendance |
|---|---|
Johnson & Johnson Innovative Medicine New Brunswick, NJ | |
Pharmaceutical business of Johnson & Johnson, formerly Janssen, with medicines in oncology, immunology and neuroscience. | Talk Tue Oct 6 11:10am From Strategic Partnering to Orchestrated Partnering: Navigating the Next Era of Precision Medicine Drug–diagnostic commercialization & access Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Chair Wed Oct 7 11:19am Stream chair Talk Wed Oct 7 12:40pm MRD in IBD? Building a Precision Medicine Consortium for Deeper Endpoints in IBD Biomarker discovery & translation Talk Wed Oct 7 2:40pm If You Build It, Will They Come? Drug–diagnostic commercialization & access Panel Wed Oct 7 5:00pm Beyond the Contract: Inside a Pharma–CDx Partnership Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Thu Oct 8 8:10am Expanding Access to Precision Cancer Care with the Precision Cancer Consortium CGP Implementation Guide Drug–diagnostic commercialization & accessClinical & companion diagnostic development Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access Panel Thu Oct 8 2:00pm Fit-for-Purpose CDx Strategies: Matching Testing Approaches to Development & Patient Access Needs Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
EMD Serono Rockland, MA | |
US and Canadian healthcare business of Merck KGaA, Darmstadt, developing medicines in oncology, neurology, immunology and fertility. | Talk Tue Oct 6 11:30am A Dual Tissue & Liquid Biopsy Strategy: The TEPMETKO® Companion Diagnostic Journey Clinical & companion diagnostic developmentLiquid biopsy & MRD Chair Wed Oct 7 8:00am Chair’s Opening Remarks Talk Wed Oct 7 11:50am Definition of the Best Practices in Clinical Utility of Liquid Biopsy: Clinical Guideline, Technologies, Cost-Effectiveness, Reimbursement, a Unidirectional or Multidirectional Path Liquid biopsy & MRDDrug–diagnostic commercialization & access Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD Chair Wed Oct 7 4:05pm Chair’s Opening Afternoon Remarks Chair Wed Oct 7 5:50pm Closing Remarks & End of Conference Day Two |
Merck Rahway, NJ | |
US pharmaceutical company, known as MSD outside the US and Canada, with oncology medicines including pembrolizumab. | Panel Tue Oct 6 12:30pm Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Tue Oct 6 2:30pm Integrating Science & Strategy to Advance Companion Diagnostic Development for Optimal Patient Treatment Clinical & companion diagnostic development Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD Panel Wed Oct 7 3:10pm Advancing Regulatory Frameworks & Standards for Compliant Digital Pathology Co-Development Digital pathology & spatial biomarkersClinical & companion diagnostic development Talk Thu Oct 8 12:20pm A Single-Cell Platform for Linking CRISPR-Edited Variants to Transcriptional Outcomes Biomarker discovery & translation Talk Thu Oct 8 12:20pm Drug Diagnostic Co-Development: Overlooked Challenges & Mitigations Clinical & companion diagnostic development |
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company with medicines in oncology, hematology, immunology and cardiovascular disease. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 3:10pm Bolstering Scalable Commercial Drug-Diagnostic Strategies to Ensure Equitable Solutions for Global Precision Oncology Applications Drug–diagnostic commercialization & access Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access |
GSK London, UK | |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 9:00am Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 12:10pm Building the Clinical & Commercial Ecosystem for AI-Enabled Precision Pathology Digital pathology & spatial biomarkersDrug–diagnostic commercialization & access Talk Thu Oct 8 9:50am When a Drug Program Expects Multiple Global Dx Partners: Considerations for Master CDx Agreements Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
Foundation Medicine Boston, MA | ◇Expertise Partner |
Comprehensive genomic profiling company offering tissue and blood cancer tests and developing companion diagnostics with drug developers. | Talk Tue Oct 6 11:30am A Dual Tissue & Liquid Biopsy Strategy: The TEPMETKO® Companion Diagnostic Journey Clinical & companion diagnostic developmentLiquid biopsy & MRD Panel Tue Oct 6 2:00pm Single-Cell Becomes a Reality: The Next Generation of Therapy Selection Biomarkers Biomarker discovery & translation |
Natera Austin, TX | ◇Expertise Partner |
Cell-free DNA testing company whose Signatera test tracks molecular residual disease, with a real-world data platform for drug developers. | Talk Tue Oct 6 8:35am What Becomes Possible Combing MRD, Multi-Omics & RWD Insights Liquid biopsy & MRDMultimodal & AI-enabled precision medicine Talk Thu Oct 8 11:00am Accelerate Early Phase Drug Development with MIIRA, Natera’s Longitudinal ctDNA & Multi-Modal Real-World Data Platform Liquid biopsy & MRDMultimodal & AI-enabled precision medicine |
Non-profit consortium of industry, academia and regulators building shared data and standards to speed development and validation of liquid biopsy assays. | Panel Tue Oct 6 3:40pm Liquid Biopsy at the Point of Care: Making ctDNA Actionable for Treatment Selection Liquid biopsy & MRD Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development |
Compass Therapeutics Boston, MA | |
Clinical-stage biotech developing antibody-based cancer therapies. | Chair Wed Oct 7 11:18am Stream chair Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD |
Biodesix Louisville, CO | ◇Program Partner |
Lung disease diagnostics company with Medicare-covered blood tests that also offers biopharma partners its testing technology and laboratory services. | Talk Wed Oct 7 11:20am Building a Fit-for-Purpose TPD Biomarker: Kinesin Quantification in PBMCs from Discovery Through Clinical Development Biomarker discovery & translation |
Instantly find 20 buyers in liquid biopsy & MRD
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World CDx 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by World CDx or its organizers. Submit a correction